The Janus Face of IL-33 Signaling in Tumor Development and Immune Escape

por Choi, Mi-Ran, Sosman, Jeffrey A., Zhang, Bin
Publicado 2021

Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors

por Fenton, Sarah E., Sosman, Jeffrey A., Chandra, Sunandana
Publicado 2019

Endocrine side effects of immune checkpoint inhibitors

por Cardona, Zulma, Sosman, Jeffrey A., Chandra, Sunandana, Huang, Wenyu
Publicado 2023

Clinically relevant genes and regulatory pathways associated with NRAS(Q61) mutations in melanoma through an integrative genomics approach

por Jiang, Wei, Jia, Peilin, Hutchinson, Katherine E., Johnson, Douglas B., Sosman, Jeffrey A., Zhao, Zhongming
Publicado 2014

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

por Costa, Ricardo, Carneiro, Benedito A., Agulnik, Mark, Rademaker, Alfred W., Pai, Sachin G., Villaflor, Victoria M., Cristofanilli, Massimo, Sosman, Jeffrey A., Giles, Francis J
Publicado 2016

A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

por Wang-Gillam, Andrea, Tew, William P., Rothenberg, Mace L., Dupont, Jakob, Cooper, Wendy, Sternas, Lars, Buzenet, Giliane, Sosman, Jeffrey A., Spriggs, David R., Lockhart, Albert Craig
Publicado 2011

Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1

por Kohrt, Holbrook, Kowanetz, Marcin, Gettinger, Scott, Powderly, John, Koeppen, Hartmut, Sosman, Jeffrey A, Cruz, Cristina, Xiao, Yuanyuan, Mokatrin, Ahmad, Fine, Gregg, Chen, Daniel S, Hodi, F Stephen
Publicado 2013

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

por Kanz, Bridgette A., Pollack, Megan H., Johnpulle, Romany, Puzanov, Igor, Horn, Leora, Morgans, Alicia, Sosman, Jeffrey A., Rapisuwon, Suthee, Conry, R. Martin, Eroglu, Zeynep, Johnson, Douglas B.
Publicado 2016

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

por Adjei, Alex A., LoRusso, Patricia, Ribas, Antoni, Sosman, Jeffrey A., Pavlick, Anna, Dy, Grace K., Zhou, Xiaofei, Gangolli, Esha, Kneissl, Michelle, Faucette, Stephanie, Neuwirth, Rachel, Bózon, Viviana
Publicado 2016

ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma

por Hutchinson, Katherine E., Johnson, Douglas B., Johnson, Adam S., Sanchez, Violeta, Kuba, Maria, Lu, Pengcheng, Chen, Xi, Kelley, Mark C., Wang, Qingguo, Zhao, Zhongming, Kris, Mark, Berger, Michael F., Sosman, Jeffrey A., Pao, William
Publicado 2015

The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020

por Ascierto, Paolo A., Atkins, Michael B., Eggermont, Alexander M., Gershenwald, Jeffrey E., Grob, Jean-Jacques, Hamid, Omid, Sondak, Vernon K., Sosman, Jeffrey A., Tawbi, Hussein A., Weber, Jeffrey S., Caracò, Corrado, Osman, Iman, Puzanov, Igor
Publicado 2021

Improved methods for RNAseq-based alternative splicing analysis

por Halperin, Rebecca F., Hegde, Apurva, Lang, Jessica D., Raupach, Elizabeth A., Legendre, Christophe, Liang, Winnie S., LoRusso, Patricia M., Sekulic, Aleksandar, Sosman, Jeffrey A., Trent, Jeffrey M., Rangasamy, Sampathkumar, Pirrotte, Patrick, Schork, Nicholas J.
Publicado 2021

The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma

por Ladomersky, Erik, Scholtens, Denise M., Kocherginsky, Masha, Hibler, Elizabeth A., Bartom, Elizabeth T., Otto-Meyer, Sebastian, Zhai, Lijie, Lauing, Kristen L., Choi, Jaehyuk, Sosman, Jeffrey A., Wu, Jennifer D., Zhang, Bin, Lukas, Rimas V., Wainwright, Derek A.
Publicado 2019

The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022

por Ascierto, Paolo A., Blank, Christian, Eggermont, Alexander M., Garbe, Claus, Gershenwald, Jeffrey E., Hamid, Omid, Hauschild, Axel, Luke, Jason J., Mehnert, Janice M., Sosman, Jeffrey A., Tawbi, Hussein A., Mandalà, Mario, Testori, Alessandro, Caracò, Corrado, Osman, Iman, Puzanov, Igor
Publicado 2023

Melanoma whole exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

por Shi, Hubing, Moriceau, Gatien, Kong, Xiangju, Lee, Mi-Kyung, Lee, Hane, Koya, Richard C., Ng, Charles, Chodon, Thinle, Scolyer, Richard A., Dahlman, Kimberly B., Sosman, Jeffrey A., Kefford, Richard F., Long, Georgina V., Nelson, Stanley F., Ribas, Antoni, Lo, Roger S.
Publicado 2012

Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies

por Zhai, Lijie, Bell, April, Ladomersky, Erik, Lauing, Kristen L., Bollu, Lakshmi, Sosman, Jeffrey A., Zhang, Bin, Wu, Jennifer D., Miller, Stephen D., Meeks, Joshua J., Lukas, Rimas V., Wyatt, Eugene, Doglio, Lynn, Schiltz, Gary E., McCusker, Robert H., Wainwright, Derek A.
Publicado 2020

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

por Fedorenko, Inna V., Abel, Ethan V., Koomen, John M., Fang, Bin, Wood, Elizabeth R., Chen, Y. Ann, Fisher, Kate J., Iyengar, Sanjana, Dahlman, Kimberly B., Wargo, Jennifer A., Flaherty, Keith T., Sosman, Jeffrey A., Sondak, Vernon K., Messina, Jane L., Gibney, Geoffrey T., Smalley, Keiran S.M.
Publicado 2015

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

por Schuler, Martin, Zimmer, Lisa, Kim, Kevin B., Sosman, Jeffrey A., Ascierto, Paolo A., Postow, Michael A., De Vos, Filip Y.F.L., van Herpen, Carla M.L., Carlino, Matteo S., Johnson, Douglas B., Berking, Carola, Reddy, Micaela B., Harney, Allison S., Berlin, Jordan D., Amaria, Rodabe N.
Publicado 2022

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)

por Atkins, Michael B., Jegede, Opeyemi A., Haas, Naomi B., McDermott, David F., Bilen, Mehmet A., Stein, Mark, Sosman, Jeffrey A., Alter, Robert, Plimack, Elizabeth R., Ornstein, Moshe, Hurwitz, Michael, Peace, David J., Signoretti, Sabina, Denize, Thomas, Cimadamore, Alessia, Wu, Catherine J., Braun, David, Einstein, David, Catalano, Paul J., Hammers, Hans
Publicado 2022

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

por Atkins, Michael B, Jegede, Opeyemi A, Haas, Naomi B, McDermott, David F, Bilen, Mehmet A, Stein, Mark, Sosman, Jeffrey A, Alter, Robert, Plimack, Elizabeth R, Ornstein, Moshe C, Hurwitz, Michael, Peace, David J, Signoretti, Sabina, Denize, Thomas, Cimadamore, Alessia, Wu, Catherine J, Braun, David, Einstein, David, Catalano, Paul J, Hammers, Hans
Publicado 2023